Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
Falcone M, Tiseo G, Marchetti G, Kalo J, Galfo V, Occhineri S, Almerigogna F, Matucci T, Riccardi N, Suardi LR, Rina I, Sijoni L, Caparello MC, Cassano Cassano R, Del Giudice ML, Franciosa M, Facella F, Tancredi G, Fazzi R, Galimberti S. Falcone M, et al. Among authors: galimberti s. Leuk Lymphoma. 2024 Oct;65(10):1474-1481. doi: 10.1080/10428194.2024.2361099. Epub 2024 Jun 4. Leuk Lymphoma. 2024. PMID: 38832710
Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series.
Fontanelli L, Pizzanelli C, Milano C, Cassano Cassano R, Galimberti S, Rossini MI, Santo I, Turco F, Bonanni E, Siciliano G, Orciuolo E, Baldacci F. Fontanelli L, et al. Among authors: galimberti s. Neurol Sci. 2023 Sep;44(9):3291-3297. doi: 10.1007/s10072-023-06841-6. Epub 2023 May 10. Neurol Sci. 2023. PMID: 37160803 Free PMC article.
Understanding mechanisms of resistance to FLT3 inhibitors in adult FLT3-mutated acute myeloid leukemia to guide treatment strategy.
Ruglioni M, Crucitta S, Luculli GI, Tancredi G, Del Giudice ML, Mechelli S, Galimberti S, Danesi R, Del Re M. Ruglioni M, et al. Among authors: galimberti s. Crit Rev Oncol Hematol. 2024 Sep;201:104424. doi: 10.1016/j.critrevonc.2024.104424. Epub 2024 Jun 23. Crit Rev Oncol Hematol. 2024. PMID: 38917943 Free article. Review.
[18F]-florbetaben PET/CT is sensitive for cardiac AL amyloidosis.
Cassano Cassano R, Genovesi D, Vergaro G, Giorgetti A, Aimo A, Del Giudice ML, Galimberti S, Emdin M, Buda G. Cassano Cassano R, et al. Among authors: galimberti s. Eur J Clin Invest. 2024 Oct;54(10):e14270. doi: 10.1111/eci.14270. Epub 2024 Jul 17. Eur J Clin Invest. 2024. PMID: 39021058
Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy.
De Muro M, Janssen AJ, Amadori S, de Fabritiis P, Sabatino D, Niscola P, Torti L, Trawinska MM, Tesei C, Bombaci F, Tarricone M, Bocchia M, Fava C, Galimberti S, Iurlo A, Luciano L, Abruzzese E. De Muro M, et al. Among authors: galimberti s. Ther Adv Hematol. 2023 Sep 6;14:20406207231190683. doi: 10.1177/20406207231190683. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37693118 Free PMC article.
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.
Breccia M, Cucci R, Marsili G, Castagnetti F, Galimberti S, Izzo B, Sorà F, Soverini S, Messina M, Piciocchi A, Bonifacio M, Cilloni D, Iurlo A, Martinelli G, Rosti G, Stagno F, Fazi P, Vignetti M, Pane F. Breccia M, et al. Among authors: galimberti s. Clin Lymphoma Myeloma Leuk. 2024 Sep 7:S2152-2650(24)01802-0. doi: 10.1016/j.clml.2024.08.009. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39322541
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Tiribelli M, Latagliata R, Breccia M, Capodanno I, Miggiano MC, Cavazzini F, Bucelli C, Attolico I, Crescenzi SL, Russo S, Annunziata M, Sorà F, Bonifacio M, Mulas O, Loglisci G, Maggi A, Binotto G, Crisà E, Scortechini AR, Leporace AP, Sancetta R, Murgano P, Abruzzese E, Stagno F, Rapezzi D, Luzi D, Vincelli I, Bocchia M, Fava C, Malato A, Crugnola M, Pizzuti M, Lunghi F, Galimberti S, Dalmazzo M, Fanin R, Scalzulli E, Foà R, Iurlo A, Saglio G, Specchia G. Tiribelli M, et al. Among authors: galimberti s. Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24. Cancer. 2023. PMID: 37354090 Free article.
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, Peano S, Franceschetto A, Monaco L, Barbieri E, Ladetto M, Musuraca G, Tosi P, Bianchi B, Bolis SAM, Pavone V, Chiarenza A, Arcari A, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Roti G, Galimberti S, Gini G, Falcinelli F, Vitolo U, Usai SV, Stefani PM, Ibatici A, Liberati AM, Pennese E, Perrone T, Versari A, Luminari S; Fondazione Italiana Linfomi (FIL). Guerra L, et al. Among authors: galimberti s. Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 May 25. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120 Clinical Trial.
462 results